文献速递白血病

儿童急性髓系白血病血液与骨髓微小残留病的临床影响

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

研究在AML08临床试验中采用流式细胞术检测儿童急性髓系白血病患者第8天和第22天血液及第22天骨髓的微小残留病(MRD)。第22天骨髓MRD阴性者中,第8天或第22天血液MRD与结局无显著相关;但第8天血液MRD对第22天骨髓MRD阳性患者的结局有高度预测价值。

要点

  • 第22天骨髓MRD阴性患者中,第8天和第22天血液MRD均与结局无显著相关。
  • 第8天血液MRD对第22天骨髓MRD阳性患者的结局有高度预测价值。
  • 第8天血液MRD不能识别第22天骨髓MRD阴性但可能复发者。

核心结论

  • 第8天血液MRD不能用于识别第22天骨髓MRD阴性且可能复发的患者,但作者认为其可识别骨髓MRD阳性且预后差、可能适合早期实验性治疗的患者。

研究设计与样本

  • 在AML08临床试验(NCT00703820)中,采用流式细胞术检测白血病特异性免疫表型,评估血液和骨髓MRD水平。
  • 血液样本于治疗第8天和第22天获取,骨髓样本于第22天获取。

主要发现

  • 第22天骨髓MRD阴性患者中,第8天和第22天血液MRD均与结局无显著相关。
  • 第8天血液MRD对第22天骨髓MRD阳性患者的结局有高度预测价值。

临床怎么用

  • 原文未据此给出推荐,仅复述作者结论:第8天血液MRD结果可识别骨髓MRD阳性且预后差的患者,这些患者可能适合早期使用实验性治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic significance of bone marrow minimal residual disease (MRD) in pediatric patients with acute myeloid leukemia (AML) is well characterized, but the impact of blood MRD is not known. We, therefore, used flow cytometric assessment of leukemia-specific immunophenotypes to measure levels of MRD in both the blood and bone marrow of patients treated in the AML08 (NCT00703820) clinical trial. Blood samples were obtained on days 8 and 22 of therapy, whereas bone marrow samples were obtained on day 22. Among patients who tested as having MRD-negative bone marrow on day 22, neither day-8 nor day-22 blood MRD was significantly associated with the outcome. However, day-8 blood MRD was highly predictive of the outcome among patients who tested as having MRD-positive bone marrow on day 22. Although the measurement of blood MRD on day 8 cannot be used to identify patients who have day-22 MRD-negative bone marrow who are likely to relapse, our findings suggest that day-8 blood MRD results can identify patients with MRD-positive bone marrow who have a dismal prognosis and may be candidates for the early use of experimental therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karol SE, Coustan-Smith E, Pounds S, et al. Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia. Blood Adv. 2023. PMID: 37058475. doi:10.1182/bloodadvances.2022009534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。